Radiation and immunotherapy for colorectal cancer that has spread
Part of Cancer, Digestive system clinical trials.
This trial tests combining focused radiation (SBRT) with immunotherapy for colorectal cancer that has spread to the liver or lungs. The goal is to see if this combination can shrink tumors and improve control of the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread or come back, and it cannot be removed with surgery.
- You have cancer spots in your liver or lungs that can be treated with focused radiation (SBRT).
- You are 18 or older and generally able to take care of yourself (performance status 0 or 1).
- You do not have untreated brain metastases, active autoimmune disease, or other serious health conditions.
- Your blood counts and organ function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving targeted high-dose radiation (SBRT) to liver metastases from colorectal cancer after initial treatment, with the goal of improving long-term control or cure. It may help people who have a limited number of liver spots that doctors think can be treated safely and effectively.
This trial tests a combination of treatments for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It uses an oncolytic virus (which infects and kills cancer cells) along with radiation, chemotherapy, targeted therapy, and immunotherapy to try to shrink the liver tumors.
This trial studies a targeted liver radiation procedure that uses tiny radioactive beads to treat colon cancer spread mostly in the liver. It may help people whose liver tumors cannot be removed or treated with other common local treatments, but it has several safety and “screening” checks.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests the combination of two immunotherapy drugs (botensilimab and balstilimab) plus targeted radiation to liver tumors. It's for people with colorectal cancer that has spread and hasn't responded to standard treatments.
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.